Abstract
The management of metastatic hormone receptor–positive (HR+) and human epidermal growth factor receptor 2–positive (HER2+) breast cancer continues to evolve with the development of novel targeted therapies. At JADPRO Live, presenters discussed therapies for this subtype of breast cancer, adverse events, management strategies, as well as biomarkers to consider when making treatment decisions.
References
Al Sukhun, S., Temin, S., Barrios, C. H., Antone, N. Z., Guerra, Y. C., Mac Gregor, M. C., Chopra, R., Danso, M. A., Gomez, H. L., Homian, N. D. M., Kandil, A., Kithaka, B., Koczwara, B., Moy, B., Nakigudde, G., Petracci, F. E., Rugo, H. S., El Saghir, N. S., & Arun, B. K. (2024). Systemic treatment of patients with metastatic breast cancer: ASCO resource-stratified guideline. JCO Global Oncology, 10, e2300285. https://doi.org/10.1200/GO.23.00285
Cortés, J., Hurvitz, S. A., Im, S. A., Iwata, H., Curigliano, G., Kim, S. B., Chiu, J. W. Y., Pedrini, J. L., Li, W., Yonemori, K., Bianchini, G., Loi, S., Borges, G. S., Wang, X., Bachelot, T., Nakatani, S., Ashfaque, S., Liang, Z., Egorov, A., & Hamilton, E. (2024). Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature Medicine, 30(8), 2208–2215. https://doi.org/10.1038/s41591-024-03021-7
Hurvitz, S. A., Hegg, R., Chung, W. P., Im, S. A., Jacot, W., Ganju, V., Chiu, J. W. Y., Xu, B., Hamilton, E., Madhusudan, S., Iwata, H., Altintas, S., Henning, J. W., Curigliano, G., Perez-Garcia, J. M., Kim, S. B., Petry, V., Huang, C. S., Li, W., Frenel, J. S.,…Cortés, J. (2023). Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet, 401(10371), 105–117. https://doi.org/10.1016/S0140-6736(22)02420-5
Metzger, O., Mandrekar, S., DeMichele, A., et al. (2024). AFT-38 PATINA: A randomized, open-label, phase III trial to evaluate the efficacy and safety of palbociclib plus anti-HER2 therapy and endocrine therapy versus anti-HER2 therapy and endocrine therapy after induction treatment for hormone receptor–positive/HER2-positive metastatic breast cancer (Abstract P2-03-20, SESS-18111). Proceedings of the San Antonio Breast Cancer Symposium. San Antonio, TX.
National Comprehensive Cancer Network. (2025). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 4.2025). https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419
Swain, S. M., Miles, D., Kim, S. B., Im, Y. H., Im, S. A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., Clark, E., Knott, A., Restuccia, E., Benyunes, M. C., Cortés, J., & CLEOPATRA study group (2020). Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. The Lancet. Oncology, 21(4), 519–530. https://doi.org/10.1016/S1470-2045(19)30863-0
Tolaney, S. M., Jiang, Z., Zhang, Q., Barroso-Sousa, R., Park, Y. H., Rimawi, M. F., Saura Manich, C., Schneeweiss, A., Toi, M., Chae, Y. S., Kemal, Y., Chaudhari, M., Yamashita, T., Casalnuovo, M., Danso, M. A., Liu, J., Shetty, J., Herbolsheimer, P. M., & Loibl, S. (2025). Trastuzumab deruxtecan plus pertuzumab versus taxane plus trastuzumab and pertuzumab for first-line treatment of patients with HER2-positive advanced or metastatic breast cancer: Interim results from DESTINY-Breast09. Journal of Clinical Oncology, 43(17_suppl), LBA1008. https://doi.org/10.1200/JCO.2025.43.17_suppl.LBA1008
